Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medivolve Inc MEDVF

Medivolve Inc. is a Canadian healthcare technology company. The Company and its subsidiaries, Medivolve Pharmacy Inc. (doing business as Marbella Pharmacy) and Kedy Ying Jao D.O., a Medical Corporation, operate a distributed network of two retail patient-care locations in California, United States. It has two business units: Medivolve Pharmacy Division (MPD) and Medivolve Clinic Services Division (MCSD). MPD provides retail pharmacy and mail-order pharmacy services related to COVID-19, antibiotics, dermatology, family medicine, immunology, neurology, pain management, pediatrics, preventive medicine and psychiatry to patients in Southern California. MCSD provides licensed healthcare through a clinic in Brea, California, United States. MCSD is focused on developing a telehealth platform, which connects patients with physicians, and facilitates and manages the provision of virtual consultation, diagnosis, and treatment services in partnership with qualified health practitioners.


OTCPK:MEDVF - Post by User

Post by Sarb99on Jan 05, 2021 1:25am
194 Views
Post# 32221813

Canaccord can show our calculations to deep-pocket investors

Canaccord can show our calculations to deep-pocket investors
Anyone thinking should have sold in the 40s probably get another chance soon. 2 more trading days before QuestCap become Medivolve Inc. It does seem everything is lining up with January 7, 2020. They could have waited to announce this on Friday after the market closed If this was such a bad deal. 
 
I don't think they will give out 20 million shares at .25 to Canaccord at the last stage before becoming profitable. There must be an agreement to buy the shares from the open market or required stock performance. 
 
Canaccord knows all kinds of investors and if they take these numbers. Those we calculate every day, how many testing sites, how many tests per day, per site and revenue per test. I am sure many of those investors will be buying at prices. If Canaccord wanted to keep buying or selling at these prices, they could do that in the open market. Like a few weeks back, QSC was trading .15 to .25 cents. Why did they need to get into private placement? 
 
In a few weeks, Medivolve should have 100 testing sites up and running. Those testing sites can generate $30 million-plus per month. So no way Medivolve will keep trading at .25-.35 cents. 
 
Yes, 20 million extra issued shares do make a difference, but if Canaccord can help to bring more investors buying Medivlve. It should be all worthwhile. 
<< Previous
Bullboard Posts
Next >>